News &

Media Contact

Amy Merves
Manager of
Media Relations



Ozols, Internationally Known for Ovarian Cancer Research and Treatment, Named to Fox Chase Cancer Center's Newest Chair Endowed by the Weg Family

PHILADELPHIA (July 5, 2002)-Fox Chase Cancer Center recently celebrated first-time appointments to three new faculty chairs, each endowed with gifts totaling $1.5 million. Robert F. Ozols, M.D., Ph.D., of Solebury, Pa., senior vice president for medical science at Fox Chase, holds the new chair in medical science, the Audrey Weg Schaus and Geoffrey Alan Weg Endowed Chair.

Fox Chase board member Kenneth E. Weg and his wife, Carol, of Princeton, N.J., endowed this chair in honor of their son and daughter.

Audrey Weg Schaus, a homemaker and new mother, lives with husband Michael and six-month-old daughter Hazel in Greenwich, Conn. Geoffrey Weg, an attorney at Manatt, Phelps and Phillips in Los Angeles, lives with his wife, Hillary, in Marina del Rey, Calif.

Carol and Kenneth Weg also endowed Fox Chase's first chair in population science, the Carol and Kenneth E. Weg Chair in Human Genetics, in 1998. With more than 33 years of experience in the pharmaceutical industry, Kenneth Weg retired last year as vice chairman of Bristol-Myers Squibb and became founder and chairman of Clearview Projects, Inc., a new company that provides planning services to biopharmaceutical companies.

"We at Fox Chase are extremely grateful and dearly indebted to the entire Weg family as the recipients of this generosity," said Fox Chase board chairman Philip E. Lippincott when he announced the new chair filled by Dr. Ozols. Ozols is known worldwide as an expert in ovarian cancer and as a leader in advancing chemotherapy research. In addition to directing the medical science division at Fox Chase, he is associate dean of Temple University School of Medicine and program director for the joint oncology program by Fox Chase and Temple University.

"He has developed new clinical approaches to treating women with ovarian cancer, including the two-drug combination of carboplatin-taxol, which is now the standard of care for women in all stages of the disease," said Fox Chase president Robert C. Young, M.D. "Bob's laboratory research has focused on how cancer cells develop drug resistance and on strategies for overcoming that resistance"-a major treatment obstacle in a number of adult cancers.

Ozols is the principal investigator for Fox Chase Cancer Center's Specialized Program of Research Excellence (SPORE) in ovarian cancer, established with a $4 million grant from the National Cancer Institute. He is currently on the board of directors of the American Society of Clinical Oncology and a former member of the oncologic drugs advisory committee of the Food and Drug Administration. He is also Fox Chase's principal investigator for the national Gynecologic Oncology Group and a past member of the governing council of the International Gynecologic Cancer Society.

For his contributions to cancer research and treatment, Ozols received the 1990 Cancer Research Award from the Milken Family Medical Foundation. In 1995 the Positive Medicine Project selected him as one of the 50 most positive physicians in America, representing the most positive role models for future physicians.

Most recently, Ozols and Young shared the prestigious 2002 Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research for their work on ovarian cancer. Ozols came to Fox Chase in 1988 from the National Cancer Institute, where he headed the experimental therapeutics section of the Medicine Branch. He joined NCI's Medicine Branch in 1976, shortly after earning his Ph.D. in biochemistry and M.D. at the University of Rochester in New York.

Thanking the Wegs for their newest endowment of a faculty chair, Ozols said, "The Weg family shares our belief that the best way to make progress against cancer is with a combined clinical and laboratory research effort. This endowed Chair will go a long way towards supporting such a program."

Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at

Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach.  For more information, call 1-888-FOX CHASE or (1-888-369-2427).

More 2002 News Releases »